Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up

Ehrlich, Rita; Ciulla, Thomas A.; Moss, A.; Harris, Alon

doi:10.1007/s00417-009-1211-6

Cited by 36 publications

(28 citation statements)

References 34 publications

(35 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are similar to those of previous studies comparing combination therapy of IVB and IVTA with IVB monotherapy. 24,25 This study showed no IOP elevation requiring use of anti-glaucoma eye drops or filtering surgery. Mean IOP elevation at 6 months after the first injection was only 0.31 mmHg in the IVB group and 0.56 mmHg in the IVB/STA group.…”

Section: Discussionmentioning

confidence: 65%

“…In one report comparing combination therapy of IVB and IVTA with IVB monotherapy, there was no advantage of combination therapy for improving vision at 6 months. 24 In another study comparing combination therapy of IVB and dexamethasone implant with IVB monotherapy, mean changes in BCVA from baseline were similar in the two groups. 26 The CMT was significantly decreased in the IVB/STA group compared with the IVB group at 1 month (P = 0.015), but there was no significant difference between the two groups at 3 and 6 months.…”

Section: Discussionmentioning

confidence: 93%

“…This result also indicates the incremental benefit of combination therapy, and it is in line with those of previous studies on combination therapy of corticosteroids and anti-VEGF agent. Ehrlich et al 24 reported that combined treatment of IVB with IVTA has the potential to reduce the frequency of repeated injections. Maturi et al 26 reported that combination therapy of IVB with dexamethasone implant requires fewer IVB reinjections than IVB monotherapy for treatment of ME due to RVO.…”

Section: Discussionmentioning

confidence: 99%

“…Thus combination therapy of corticosteroids and anti-VEGF has been attempted in clinical practice expecting a synergistic effect. [24][25][26][27] Ehrlich et al 24 reported that combining IVTA with IVB seems to offer no advantage over IVB alone for improving vision in BRVO, but it has the potential to reduce the frequency of repeated injections. And, to the best of our knowledge, no study evaluating the benefit of combination therapy of IVB with a single simultaneous STA compared with IVB monotherapy for treatment of ME secondary to BRVO has been reported, therefore, the aim of this study was to evaluate the benefit of combination therapy of IVB with a single simultaneous STA.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Moon

Kim

Sagong

2016

Eye

View full text Add to dashboard Cite

Purpose To evaluate efficacy and safety of combination therapy of intravitreal bevacizumab (IVB) with single simultaneous posterior subtenon triamcinolone acetonide (STA) for treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods This was a prospective, randomized, interventional comparative study conducted in 45 eyes with ME secondary to BRVO who were treated primarily with IVB 1.25 mg (23 eyes, IVB group) or combination therapy of IVB 1.25 mg with a single simultaneous STA 40 mg (18 eyes, IVB/STA group). Reinjections were performed with IVB if optical coherence tomography (OCT) showed recurrent ME associated with decreased visual acuity. The main outcome measurement was the number of additional IVB injections, and changes of best-corrected visual acuity (BCVA) and central macular thickness (CMT) during a 6-month follow-up period were compared. Results BCVA showed significant improvement in two groups at 6 months. In addition, CMT showed significant decrease in two groups at 6 months. No significant differences in the change of BCVA and CMT at 6 months after injection (P = 0.973, P = 0.639) were observed between the two groups. A statistically significant difference was found regarding the number of additional IVB injections (IVB group 0.96 ± 0.83; IVB/STA group 0.44 ± 0.70, P = 0.034).Conclusion Although combination therapy of IVB with a single simultaneous STA for treatment of ME secondary to BRVO did not affect the visual outcomes compared with IVB monotherapy, it had a benefit of reducing the number of additional IVB injections.

show abstract

Section: Discussionmentioning

confidence: 65%

Section: Discussionmentioning

confidence: 93%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Combination therapy of intravitreal bevacizumab with single simultaneous posterior subtenon triamcinolone acetonide for macular edema due to branch retinal vein occlusion

Moon

Kim

Sagong

2016

Eye

View full text Add to dashboard Cite

show abstract

“…Dear Editor, We read with interest the article "Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up" by Ehrlich et al [1]. We congratulate the authors for their interesting study and offer our comments.…”

mentioning

confidence: 98%